[HTML][HTML] P2X3 and P2X2/3 Receptors Inhibition Produces a Consistent Analgesic Efficacy: A Systematic Review and Meta-Analysis of Preclinical Studies
MÁ Huerta, D Marcos-Frutos, J de la Nava… - European Journal of …, 2024 - Elsevier
Abstract Background P2X3 and P2X2/3 receptors are promising therapeutic targets for pain
treatment and selective inhibitors are under evaluation in ongoing clinical trials. Here we …
treatment and selective inhibitors are under evaluation in ongoing clinical trials. Here we …
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
L Guilleminault, S Grassin-Delyle, SB Mazzone - Drugs, 2024 - Springer
Refractory chronic cough is a disabling disease with very limited therapeutic options. A
better understanding of cough pathophysiology has led to the development of emerging …
better understanding of cough pathophysiology has led to the development of emerging …
Efficacy of behavioral cough suppression therapy for refractory chronic cough or unexplained chronic cough: a meta-analysis of randomized controlled trials
B Yi, S Wang, X Xu, L Yu - Therapeutic Advances in …, 2024 - journals.sagepub.com
Background: The efficacy of behavioral cough suppression therapy (BCST) for refractory
chronic cough (RCC) and unexplained chronic cough (UCC) remains unclear due to limited …
chronic cough (RCC) and unexplained chronic cough (UCC) remains unclear due to limited …
P2X3 and P2X2/3 receptors inhibition produces a consistent analgesic efficacy: A systematic review and meta-analysis of preclinical studies
MÁ Huerta-Martínez, D Marcos-Frutos, J de la Nava… - 2024 - digibug.ugr.es
Background: P2X3 and P2X2/3 receptors are promising therapeutic targets for pain
treatment and selective inhibitors are under evaluation in ongoing clinical trials. Here we …
treatment and selective inhibitors are under evaluation in ongoing clinical trials. Here we …